Cite This Page

Citation styles for Basic safety concerns when utilizing nonergot dopamine agonists to deal with Parkinsons condition

APA style

Basic safety concerns when utilizing nonergot dopamine agonists to deal with Parkinsons condition. (2024, January 30). OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . Retrieved 07:34, May 23, 2024 from https://news.npo.digital/index.php?title=Basic_safety_concerns_when_utilizing_nonergot_dopamine_agonists_to_deal_with_Parkinsons_condition&oldid=628110.

MLA style

"Basic safety concerns when utilizing nonergot dopamine agonists to deal with Parkinsons condition." OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, . 30 Jan 2024, 11:37 UTC. 23 May 2024, 07:34 <https://news.npo.digital/index.php?title=Basic_safety_concerns_when_utilizing_nonergot_dopamine_agonists_to_deal_with_Parkinsons_condition&oldid=628110>.

MHRA style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, 'Basic safety concerns when utilizing nonergot dopamine agonists to deal with Parkinsons condition', OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , 30 January 2024, 11:37 UTC, <https://news.npo.digital/index.php?title=Basic_safety_concerns_when_utilizing_nonergot_dopamine_agonists_to_deal_with_Parkinsons_condition&oldid=628110> [accessed 23 May 2024]

Chicago style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors, "Basic safety concerns when utilizing nonergot dopamine agonists to deal with Parkinsons condition," OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, , https://news.npo.digital/index.php?title=Basic_safety_concerns_when_utilizing_nonergot_dopamine_agonists_to_deal_with_Parkinsons_condition&oldid=628110 (accessed May 23, 2024).

CBE/CSE style

OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK contributors. Basic safety concerns when utilizing nonergot dopamine agonists to deal with Parkinsons condition [Internet]. OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK, ; 2024 Jan 30, 11:37 UTC [cited 2024 May 23]. Available from: https://news.npo.digital/index.php?title=Basic_safety_concerns_when_utilizing_nonergot_dopamine_agonists_to_deal_with_Parkinsons_condition&oldid=628110.

Bluebook style

Basic safety concerns when utilizing nonergot dopamine agonists to deal with Parkinsons condition, https://news.npo.digital/index.php?title=Basic_safety_concerns_when_utilizing_nonergot_dopamine_agonists_to_deal_with_Parkinsons_condition&oldid=628110 (last visited May 23, 2024).

BibTeX entry

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Basic safety concerns when utilizing nonergot dopamine agonists to deal with Parkinsons condition --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "https://news.npo.digital/index.php?title=Basic_safety_concerns_when_utilizing_nonergot_dopamine_agonists_to_deal_with_Parkinsons_condition&oldid=628110",
   note = "[Online; accessed 23-May-2024]"
 }

When using the LaTeX package url (\usepackage{url} somewhere in the preamble) which tends to give much more nicely formatted web addresses, the following may be preferred:

 @misc{ wiki:xxx,
   author = "OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK",
   title = "Basic safety concerns when utilizing nonergot dopamine agonists to deal with Parkinsons condition --- OPENN - EUROPESE OMROEP - OFFICIAL PUBLIC EUROPEAN NETHERLANDS NETWORK{,} ",
   year = "2024",
   url = "\url{https://news.npo.digital/index.php?title=Basic_safety_concerns_when_utilizing_nonergot_dopamine_agonists_to_deal_with_Parkinsons_condition&oldid=628110}",
   note = "[Online; accessed 23-May-2024]"
 }